ClinicalTrials.gg
CompletedNCT00262600Updated Apr 17, 2019Results posted

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

A Phase 3 interventional study of warfarin and Dabigatran dose 1 in Atrial Fibrillation and Stroke, sponsored by Boehringer Ingelheim. Completed at 984 sites in 44 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-17.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
18,113
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing warfarin in Atrial Fibrillation — 1 open to participants now, 1 under way, none of them phase 3. Warfarin · Atrial Fibrillation.

Enrollment
Largest of 25
18,113 · median 203
Started
2005
with 1 other
Phase 3
5 of 26
none open now
Registered
5th of 26
by date
Lead sponsor
1 of 26
Boehringer Ingelheim

Among the 26 studies testing warfarin in Atrial Fibrillation, this one has the largest enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2005, is one of 5 in phase 3, and was the 5th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

1 of the 26 studies testing warfarin in Atrial Fibrillation is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About warfarin

Warfarin: first FDA approval 1954 (COUMADIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing warfarin in Atrial Fibrillation, or all of them as a file.
02

Study summary

The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.

03

Conditions studied

  • Atrial Fibrillation
  • Stroke
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria Patients with non-valvular atrial fibrillation (AF), at moderate to high risk of stroke, or systemic embolism with at least one additional risk factor (i.e. previous ischemic stroke, , or systemic embolism, left ventricular dysfunction, age >=75 years, age >=65 with either diabetes mellitus, history of coronary artery disease or hypertension)

Exclusion criteria

  1. Prosthetic heart valves requiring anticoagulation per se, or hemodynamically relevant valve disease that is expected to require surgical intervention during the course of the study
  2. Severe, disabling stroke within the previous 6 months, or any stroke within the previous 14 days
  3. Conditions associated with an increased risk of bleeding
  4. to warfarin treatment
  5. Reversible causes of atrial fibrillation (e.g., cardiac surgery, pulmonary embolism, untreated hyperthyroidism).
  6. Plan to perform a pulmonary vein ablation or surgery for cure of the AF
  7. Severe renal impairment (estimated \<=30 mL/min)
  8. Active infective endocarditis
  9. Active liver disease
  10. Women who are pregnant, lactating, or of who refuse to use a medically acceptable form of throughout the study
  11. Anaemia ( \<100g/L) or thrombocytopenia ( count \<100 x 109/L)
  12. Patients who have developed transaminase elevations upon exposure to ximelagatran
  13. Patients who have received an drug in the past 30 days or are participating in another drug study
  14. Patients considered unreliable by the investigator concerning the requirements for follow-up during the study and/or compliance with study drug administration, has a less than the expected duration of the trial due to concomitant disease, or has any condition which in the opinion of the investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse)
  15. Any known to galactose if the warfarin used contains galactose.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Enrollment
18,113 participants (actual)

Study arms

  • Active comparator
    Dabigatran dose 2

    twice a day

    Drug: Dabigatran dose 2

  • Active comparator
    Warfarin

    once a day

    Drug: warfarin

  • Active comparator
    Dabigatran dose 1

    twice a day

    Drug: Dabigatran dose 1

Interventions

  • once a day

  • DrugDabigatran dose 1

    twice daily

  • DrugDabigatran dose 2

    twice a day

06

What researchers measure

Primary outcomes

  1. Yearly Event Rate for Composite Endpoint of Stroke/SEE

    Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25

    Time frame: 36 months

Secondary outcomes

  1. Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death

    Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25

    Time frame: 36 months

  2. Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death

    Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25

    Time frame: 36 months

  3. Bleeding Events (Major and Minor)

    Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 Major bleeds are adjudicated, whereas minor bleeds are investigator reported.

    Time frame: 36 months

  4. Clinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH)

    Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH)

    Time frame: 36 months

  5. Abnormal Liver Function Test

    Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST\>3xULN and total bilirubin \> 2 x ULN

    Time frame: 36 months

07

Results

Posted Feb 10, 2011

Participant flow

Participant flow — Overall Study
MilestoneDabigatran 110 mgDabigatran 150 mgWarfarin
Started601560766022
Completed578058245756
Not completed235252266
Withdrew: Lost to follow-up173141
Withdrew: Withdrawal by subject128145139
Withdrew: Not treated321724
Withdrew: Other585962

Outcome measures

PrimaryYearly Event Rate for Composite Endpoint of Stroke/SEE

Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25

Time frame:
36 months
Reported as:
Number · yearly event rate (percentage)
Yearly Event Rate for Composite Endpoint of Stroke/SEE
yearly event rate (percentage)Dabigatran 110 mgDabigatran 150 mgWarfarin
Yearly Event Rate for Composite Endpoint of Stroke/SEE1.541.111.71
Statistical analysis
  • Dabigatran 110 mg vs Warfarin · Regression, Cox · p = <.0001 (p-value for protocol specified margin of 1.46) · Cox proportional hazard: 0.90 · 95% CI 0.74 to 1.10
  • Dabigatran 150 mg vs Warfarin · Regression, Cox · p = <.0001 (p-value for protocol specified margin of 1.46) · Cox proportional hazard: 0.65 · 95% CI 0.52 to 0.81
SecondaryYearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death

Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25

Time frame:
36 months
Reported as:
Number · yearly event rate (percentage)
Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death
yearly event rate (percentage)Dabigatran 110 mgDabigatran 150 mgWarfarin
Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death4.854.325.20
Statistical analysis
  • Dabigatran 110 mg vs Warfarin · Regression, Cox · p = 0.2206 (p-value is for superiority testing) · Cox proportional hazard: 0.93 · 95% CI 0.83 to 1.04Comparisons between treatment groups were performed using a Cox regression analysis with treatment in the model.
  • Dabigatran 150 mg vs Warfarin · Regression, Cox · p = 0.0015 (p-value is for superiority testing) · Cox proportional hazard: 0.83 · 95% CI 0.74 to 0.93Comparisons between treatment groups were performed using a Cox regression analysis with treatment in the model.
SecondaryYearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death

Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25

Time frame:
36 months
Reported as:
Number · yearly event rate (percentage)
Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death
yearly event rate (percentage)Dabigatran 110 mgDabigatran 150 mgWarfarin
Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death4.263.684.35
Statistical analysis
  • Dabigatran 110 mg vs Warfarin · Regression, Cox · p = 0.7508 (p-value is for superiority testing) · Cox proportional hazard: 0.98 · 95% CI 0.87 to 1.11Comparisons between treatment groups were performed using a Cox regression analysis with treatment in the model.
  • Dabigatran 150 mg vs Warfarin · Regression, Cox · p = 0.0093 (p-value is for superiority testing) · Cox proportional hazard: 0.84 · 95% CI 0.74 to 0.96Comparisons between treatment groups were performed using a Cox regression analysis with treatment in the model.
SecondaryBleeding Events (Major and Minor)

Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 Major bleeds are adjudicated, whereas minor bleeds are investigator reported.

Time frame:
36 months
Reported as:
Number · yearly event rate (percentage)
Bleeding Events (Major and Minor)
yearly event rate (percentage)Dabigatran 110 mgDabigatran 150 mgWarfarin
Major bleeds2.993.553.81
Minor bleeds13.1614.8516.37
Statistical analysis
  • Dabigatran 110 mg vs Warfarin · Regression, Cox · p = 0.0026 (p-value is for superiority testing) · Cox proportional hazard: 0.80 · 95% CI 0.70 to 0.93Comparisons between treatment groups were performed using Cox regression analysis with treatment in the model.
  • Dabigatran 150 mg vs Warfarin · Regression, Cox · p = 0.3146 (p-value is for superiority testing) · Cox proportional hazard: 0.93 · 95% CI 0.81 to 1.07Comparisons between treatment groups were performed using Cox regression analysis with treatment in the model.
SecondaryClinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH)

Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH)

Time frame:
36 months
Reported as:
Number · yearly event rate (percentage)]
Clinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH)
yearly event rate (percentage)]Dabigatran 110 mgDabigatran 150 mgWarfarin
intracerebral hemorrhage0.120.100.38
intracranial hemorrhage (ICH)0.230.320.76
Statistical analysis
  • Dabigatran 110 mg vs Warfarin · Regression, Cox · p = <0.0001 (p-value is for superiority testing) · Cox proportional hazard: 0.30 · 95% CI 0.19 to 0.45Comparisons between treatment groups were performed using Cox regression analysis with treatment in the model.
  • Dabigatran 150 mg vs Warfarin · Regression, Cox · p = <0.0001 (p-value is for superiority testing) · Cox proportional hazard: 0.41 · 95% CI 0.28 to 0.60Comparisons between treatment groups were performed using Cox regression analysis with treatment in the model.
SecondaryAbnormal Liver Function Test

Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST\>3xULN and total bilirubin \> 2 x ULN

Time frame:
36 months
Reported as:
Number · participants
Abnormal Liver Function Test
participantsDabigatran 110 mgDabigatran 150 mgWarfarin
Abnormal Liver Function Test111421

Adverse events

Collected over 36 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dabigatran 110 mg—1,263/5,983 (21.1%)2,286/5,983 (38.2%)
Dabigatran 150 mg—1,289/6,059 (21.3%)2,273/6,059 (37.5%)
Warfarin—1,357/5,998 (22.6%)2,118/5,998 (35.3%)
Most frequent serious events
Showing 10 of 1,448
Most frequent serious events
EventDabigatran 110 mgDabigatran 150 mgWarfarin
Cardiac failure congestiveCardiac disorders83/598358/605973/5998
PneumoniaInfections and infestations74/598370/605962/5998
Atrial fibrillationCardiac disorders64/598355/605974/5998
Cardiac failureCardiac disorders51/598362/605965/5998
Gastrointestinal haemorrhageGastrointestinal disorders38/598355/605941/5998
AnaemiaBlood and lymphatic system disorders34/598347/605933/5998
Chest painGeneral disorders29/598345/605946/5998
DyspnoeaRespiratory, thoracic and mediastinal disorders38/598343/605945/5998
FallInjury, poisoning and procedural complications22/598329/605943/5998
Renal failure acuteRenal and urinary disorders42/598338/605935/5998
Most frequent other events
Showing 10 of 11
Most frequent other events
EventDabigatran 110 mgDabigatran 150 mgWarfarin
DizzinessNervous system disorders442/5983440/6059536/5998
DyspnoeaRespiratory, thoracic and mediastinal disorders460/5983483/6059506/5998
Oedema peripheralGeneral disorders436/5983439/6059440/5998
FatigueGeneral disorders367/5983361/6059341/5998
DyspepsiaGastrointestinal disorders362/5983344/605983/5998
DiarrhoeaGastrointestinal disorders347/5983360/6059308/5998
CoughRespiratory, thoracic and mediastinal disorders318/5983308/6059343/5998
NasopharyngitisInfections and infestations315/5983309/6059327/5998
Back painMusculoskeletal and connective tissue disorders281/5983272/6059322/5998
ArthralgiaMusculoskeletal and connective tissue disorders246/5983306/6059318/5998

Baseline characteristics

Age, Continuous
Age, Continuous(years)Dabigatran 110 mgDabigatran 150 mgWarfarinTotal
Mean71.4 ± 8.671.5 ± 8.871.6 ± 8.671.5 ± 8.7
Age, Customized
Age, Customized(Participants)Dabigatran 110 mgDabigatran 150 mgWarfarinTotal
<6599810309532981
65<= and <752668258026467894
>=752349246624237238
Sex/Gender, Customized
Sex/Gender, Customized(participants)Dabigatran 110 mgDabigatran 150 mgWarfarinTotal
Male38653840380911514
Female2149223622136598
Missing1001
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dabigatran 110 mgDabigatran 150 mgWarfarinTotal
Not Hispanic or Latino55935660561516868
Hispanic or Latino4214164071244
Unknown or Not Reported1001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Dabigatran 110 mgDabigatran 150 mgWarfarinTotal
White42084268420312679
Black525767176
Asian9559659552875
Other7997867972382
Missing1001
Region of Enrollment
Region of Enrollment(participants)Dabigatran 110 mgDabigatran 150 mgWarfarinTotal
USA, Canada2166220021676533
Central Europe7077067062119
Western Europe1544155515524651
Latin America320320316956
Asia9239339262782
Other3553623551072
Smoking history
Smoking history(participants)Dabigatran 110 mgDabigatran 150 mgWarfarinTotal
Non-smoker2941299330068940
Smoker4404474481335
Ex-smoker2633263625677836
Missing1012
Regular Alcohol Consumption
Regular Alcohol Consumption(participants)Dabigatran 110 mgDabigatran 150 mgWarfarinTotal
No40174077404012134
Yes1996199919815976
Missing2013
08

Study locations

984 sites
  • 1160.26.0009 Boehringer Ingelheim Investigational Site
    Birmingham, Alabama, United States
  • 1160.26.0046 Boehringer Ingelheim Investigational Site
    Birmingham, Alabama, United States
  • 1160.26.0057 Boehringer Ingelheim Investigational Site
    Birmingham, Alabama, United States
  • 1160.26.0211 Boehringer Ingelheim Investigational Site
    Birmingham, Alabama, United States
  • 1160.26.0206 Boehringer Ingelheim Investigational Site
    Huntsville, Alabama, United States
  • 1160.26.0115 Boehringer Ingelheim Investigational Site
    Mobile, Alabama, United States
  • 1160.26.0104 Boehringer Ingelheim Investigational Site
    Lake Havasu City, Arizona, United States
  • 1160.26.0304 Boehringer Ingelheim Investigational Site
    Peoria, Arizona, United States
  • 1160.26.0185 Boehringer Ingelheim Investigational Site
    Tucson, Arizona, United States
  • 1160.26.0305 Boehringer Ingelheim Investigational Site
    Tucson, Arizona, United States
  • 1160.26.0038 Boehringer Ingelheim Investigational Site
    Hot Springs, Arkansas, United States
  • 1160.26.0302 Boehringer Ingelheim Investigational Site
    Jonesboro, Arkansas, United States
  • 1160.26.0121 Boehringer Ingelheim Investigational Site
    Little Rock, Arkansas, United States
  • 1160.26.0191 Boehringer Ingelheim Investigational Site
    Little Rock, Arkansas, United States
  • 1160.26.0204 Boehringer Ingelheim Investigational Site
    Little Rock, Arkansas, United States
  • 1160.26.0213 Boehringer Ingelheim Investigational Site
    Little Rock, Arkansas, United States
  • 1160.26.0455 Boehringer Ingelheim Investigational Site
    Little Rock, Arkansas, United States
  • 1160.26.0388 Boehringer Ingelheim Investigational Site
    Anaheim, California, United States
  • 1160.26.0441 Boehringer Ingelheim Investigational Site
    Carmichael, California, United States
  • 1160.26.0145 Boehringer Ingelheim Investigational Site
    French Camp, California, United States
  • 1160.26.0333 Boehringer Ingelheim Investigational Site
    Fullerton, California, United States
  • 1160.26.0384 Boehringer Ingelheim Investigational Site
    La Jolla, California, United States
  • 1160.26.0091 Boehringer Ingelheim Investigational Site
    La Mesa, California, United States
  • 1160.26.0246 Boehringer Ingelheim Investigational Site
    Lancaster, California, United States
  • 1160.26.0345 Boehringer Ingelheim Investigational Site
    Larkspur, California, United States
  • 1160.26.0217 Boehringer Ingelheim Investigational Site
    Loma Linda, California, United States
  • 1160.26.0059 Boehringer Ingelheim Investigational Site
    Los Angeles, California, United States
  • 1160.26.0088 Boehringer Ingelheim Investigational Site
    Los Angeles, California, United States
  • 1160.26.0337 Boehringer Ingelheim Investigational Site
    Los Angeles, California, United States
  • 1160.26.0326 Boehringer Ingelheim Investigational Site
    Mather, California, United States
  • 1160.26.0070 Boehringer Ingelheim Investigational Site
    Merced, California, United States
  • 1160.26.0349 Boehringer Ingelheim Investigational Site
    Oakland, California, United States
  • 1160.26.0016 Boehringer Ingelheim Investigational Site
    Oceanside, California, United States
  • 1160.26.0087 Boehringer Ingelheim Investigational Site
    Palm Springs, California, United States
  • 1160.26.0459 Boehringer Ingelheim Investigational Site
    Pasadena, California, United States
  • 1160.26.0216 Boehringer Ingelheim Investigational Site
    Redondo Beach, California, United States
  • 1160.26.0135 Boehringer Ingelheim Investigational Site
    Riverside, California, United States
  • 1160.26.0162 Boehringer Ingelheim Investigational Site
    Sacramento, California, United States
  • 1160.26.0300 Boehringer Ingelheim Investigational Site
    Sacramento, California, United States
  • 1160.26.0371 Boehringer Ingelheim Investigational Site
    Sacramento, California, United States
  • 1160.26.0116 Boehringer Ingelheim Investigational Site
    San Diego, California, United States
  • 1160.26.0148 Boehringer Ingelheim Investigational Site
    San Diego, California, United States
  • 1160.26.0270 Boehringer Ingelheim Investigational Site
    San Diego, California, United States
  • 1160.26.0284 Boehringer Ingelheim Investigational Site
    San Diego, California, United States
  • 1160.26.0351 Boehringer Ingelheim Investigational Site
    Santa Ana, California, United States
  • 1160.26.0043 Boehringer Ingelheim Investigational Site
    Santa Rosa, California, United States
  • 1160.26.0462 Boehringer Ingelheim Investigational Site
    Sylmar, California, United States
  • 1160.26.0276 Boehringer Ingelheim Investigational Site
    Torrance, California, United States
  • 1160.26.0379 Boehringer Ingelheim Investigational Site
    Walnut Creek, California, United States
  • 1160.26.0419 Boehringer Ingelheim Investigational Site
    Aurora, Colorado, United States
  • 1160.26.0321 Boehringer Ingelheim Investigational Site
    Colorado Springs, Colorado, United States
  • 1160.26.0449 Boehringer Ingelheim Investigational Site
    Colorado Springs, Colorado, United States
  • 1160.26.0360 Boehringer Ingelheim Investigational Site
    Denver, Colorado, United States
  • 1160.26.0413 Boehringer Ingelheim Investigational Site
    Denver, Colorado, United States
  • 1160.26.0362 Boehringer Ingelheim Investigational Site
    Fort Collins, Colorado, United States
  • 1160.26.0399 Boehringer Ingelheim Investigational Site
    Greeley, Colorado, United States
  • 1160.26.0058 Boehringer Ingelheim Investigational Site
    Bridgeport, Connecticut, United States
  • 1160.26.0241 Boehringer Ingelheim Investigational Site
    Bridgeport, Connecticut, United States
  • 1160.26.0278 Boehringer Ingelheim Investigational Site
    Bridgeport, Connecticut, United States
  • 1160.26.0085 Boehringer Ingelheim Investigational Site
    Fairfield, Connecticut, United States
  • 1160.26.0482 Boehringer Ingelheim Investigational Site
    Guilford, Connecticut, United States
  • 1160.26.0366 Boehringer Ingelheim Investigational Site
    Newark, Delaware, United States
  • 1160.26.0343 Boehringer Ingelheim Investigational Site
    Washington, District of Columbia, United States
  • 1160.26.0022 Boehringer Ingelheim Investigational Site
    Atlantis, Florida, United States
  • 1160.26.0382 Boehringer Ingelheim Investigational Site
    Boynton Beach, Florida, United States
  • 1160.26.0056 Boehringer Ingelheim Investigational Site
    Brandon, Florida, United States
  • 1160.26.0105 Boehringer Ingelheim Investigational Site
    Clearwater, Florida, United States
  • 1160.26.0296 Boehringer Ingelheim Investigational Site
    Clearwater, Florida, United States
  • 1160.26.0429 Boehringer Ingelheim Investigational Site
    Clearwater, Florida, United States
  • 1160.26.0376 Boehringer Ingelheim Investigational Site
    Daytona Beach, Florida, United States
  • 1160.26.0411 Boehringer Ingelheim Investigational Site
    Deerfield Beach, Florida, United States
  • 1160.26.0074 Boehringer Ingelheim Investigational Site
    Fort Myers, Florida, United States
  • 1160.26.0239 Boehringer Ingelheim Investigational Site
    Gainesville, Florida, United States
  • 1160.26.0260 Boehringer Ingelheim Investigational Site
    Hollywood, Florida, United States
  • 1160.26.0265 Boehringer Ingelheim Investigational Site
    Hollywood, Florida, United States
  • 1160.26.0100 Boehringer Ingelheim Investigational Site
    Inverness, Florida, United States
  • 1160.26.0209 Boehringer Ingelheim Investigational Site
    Jacksonville Beach, Florida, United States
  • 1160.26.0033 Boehringer Ingelheim Investigational Site
    Jacksonville, Florida, United States
  • 1160.26.0089 Boehringer Ingelheim Investigational Site
    Jacksonville, Florida, United States
  • 1160.26.0232 Boehringer Ingelheim Investigational Site
    Jacksonville, Florida, United States
  • 1160.26.0240 Boehringer Ingelheim Investigational Site
    Jacksonville, Florida, United States
  • 1160.26.0427 Boehringer Ingelheim Investigational Site
    Jacksonville, Florida, United States
  • 1160.26.0464 Boehringer Ingelheim Investigational Site
    Jacksonville, Florida, United States
  • 1160.26.0012 Boehringer Ingelheim Investigational Site
    Lakeland, Florida, United States
  • 1160.26.0259 Boehringer Ingelheim Investigational Site
    Melbourne, Florida, United States
  • 1160.26.0358 Boehringer Ingelheim Investigational Site
    Melbourne, Florida, United States
  • 1160.26.0034 Boehringer Ingelheim Investigational Site
    Miami, Florida, United States
  • 1160.26.0199 Boehringer Ingelheim Investigational Site
    Miami, Florida, United States
  • 1160.26.0227 Boehringer Ingelheim Investigational Site
    Orlando, Florida, United States
  • 1160.26.0095 Boehringer Ingelheim Investigational Site
    Ormond Beach, Florida, United States
  • 1160.26.0037 Boehringer Ingelheim Investigational Site
    Pensacola, Florida, United States
  • 1160.26.0076 Boehringer Ingelheim Investigational Site
    Pensacola, Florida, United States
  • 1160.26.0081 Boehringer Ingelheim Investigational Site
    Pensacola, Florida, United States
  • 1160.26.0111 Boehringer Ingelheim Investigational Site
    Pensacola, Florida, United States
  • 1160.26.0137 Boehringer Ingelheim Investigational Site
    Port Charlotte, Florida, United States
  • 1160.26.0389 Boehringer Ingelheim Investigational Site
    Port Charlotte, Florida, United States
  • 1160.26.0417 Boehringer Ingelheim Investigational Site
    Port Charlotte, Florida, United States
  • 1160.26.0332 Boehringer Ingelheim Investigational Site
    Rockledge, Florida, United States
  • 1160.26.0226 Boehringer Ingelheim Investigational Site
    Safety Harbor, Florida, United States
  • 1160.26.0015 Boehringer Ingelheim Investigational Site
    Saint Petersburg, Florida, United States

Showing the first 100 of 984 sites across 44 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Reinhardt SW, Desai NR, Tang Y, Jones PG, Ader J, Spertus JA. Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial. PLoS One. 2021 Aug 19;16(8):e0256338. doi: 10.1371/journal.pone.0256338. eCollection 2021. PubMed 34411158 ↗
  • Pol T, Hijazi Z, Lindback J, Oldgren J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Siegbahn A, Wallentin L. Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovasc Res. 2022 Jul 20;118(9):2112-2123. doi: 10.1093/cvr/cvab262. PubMed 34358298 ↗
  • Millenaar D, Schumacher H, Brueckmann M, Eikelboom JW, Ezekowitz M, Slawik J, Ewen S, Ukena C, Wallentin L, Connolly S, Yusuf S, Bohm M. Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). Am J Cardiol. 2021 Jun 15;149:27-35. doi: 10.1016/j.amjcard.2021.03.024. Epub 2021 Mar 20. PubMed 33757788 ↗
  • Pol T, Hijazi Z, Lindback J, Alexander JH, Bahit MC, De Caterina R, Eikelboom JW, Ezekowitz MD, Gersh BJ, Granger CB, Hylek EM, Lopes R, Siegbahn A, Wallentin L. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. Open Heart. 2021 Mar;8(1):e001471. doi: 10.1136/openhrt-2020-001471. PubMed 33741689 ↗
  • Hijazi Z, Wallentin L, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Pol T, Yusuf S, Oldgren J, Siegbahn A. Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. J Am Heart Assoc. 2020 Dec 15;9(24):e018984. doi: 10.1161/JAHA.120.018984. Epub 2020 Dec 9. PubMed 33292046 ↗
  • Wallentin L, Lindback J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Oldgren J, Siegbahn A. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020 Nov 1;41(41):4037-4046. doi: 10.1093/eurheartj/ehaa697. PubMed 32984892 ↗
  • Bohm M, Brueckmann M, Eikelboom JW, Ezekowitz M, Frassdorf M, Hijazi Z, Hohnloser SH, Mahfoud F, Schmieder RE, Schumacher H, Wallentin L, Yusuf S. Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. Eur Heart J. 2020 Aug 7;41(30):2848-2859. doi: 10.1093/eurheartj/ehaa247. PubMed 32385506 ↗
  • Stam-Slob MC, Connolly SJ, van der Graaf Y, van der Leeuw J, Dorresteijn JAN, Eikelboom JW, Peters RJG, Alings M, Visseren FLJ. Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. Circulation. 2019 Jun 18;139(25):2846-2856. doi: 10.1161/CIRCULATIONAHA.118.035266. Epub 2019 May 3. PubMed 31046423 ↗
  • Hijazi Z, Verdecchia P, Oldgren J, Andersson U, Reboldi G, Di Pasquale G, Mazzotta G, Angeli F, Eikelboom JW, Ezekowitz MD, Connolly SJ, Yusuf S, Wallentin L. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE - LY Trial. J Am Heart Assoc. 2019 Jan 22;8(2):e010107. doi: 10.1161/JAHA.118.010107. PubMed 30651032 ↗
  • Kent AP, Brueckmann M, Fraessdorf M, Connolly SJ, Yusuf S, Eikelboom JW, Oldgren J, Reilly PA, Wallentin L, Ezekowitz MD. Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018 Jul 17;72(3):255-267. doi: 10.1016/j.jacc.2018.04.063. Epub 2018 Jul 9. PubMed 30012318 ↗
  • Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. Am Heart J. 2018 Apr;198:169-177. doi: 10.1016/j.ahj.2017.10.015. Epub 2018 Jan 5. No abstract available. PubMed 29653640 ↗
  • Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L; ARISTOTLE and RE-LY Investigators. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018 Feb 7;39(6):477-485. doi: 10.1093/eurheartj/ehx584. PubMed 29069359 ↗
  • Verdecchia P, Reboldi G, Angeli F, Mazzotta G, Lip GYH, Brueckmann M, Kleine E, Wallentin L, Ezekowitz MD, Yusuf S, Connolly SJ, Di Pasquale G. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study. Europace. 2018 Feb 1;20(2):253-262. doi: 10.1093/europace/eux022. PubMed 28520924 ↗
  • Lauw MN, Eikelboom JW, Coppens M, Wallentin L, Yusuf S, Ezekowitz M, Oldgren J, Nakamya J, Wang J, Connolly SJ. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017 Jul;103(13):1015-1023. doi: 10.1136/heartjnl-2016-310358. Epub 2017 Feb 17. PubMed 28213368 ↗
  • Oldgren J, Hijazi Z, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L; RE-LY and ARISTOTLE Investigators. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation. 2016 Nov 29;134(22):1697-1707. doi: 10.1161/CIRCULATIONAHA.116.022802. Epub 2016 Aug 28. PubMed 27569438 ↗
  • Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, Clemens A, Reilly PA, Connolly SJ, Yusuf S, Wallentin L. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation. 2016 Aug 23;134(8):589-98. doi: 10.1161/CIRCULATIONAHA.115.020950. Epub 2016 Aug 5. PubMed 27496855 ↗
  • Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016 Jun 4;387(10035):2302-2311. doi: 10.1016/S0140-6736(16)00741-8. Epub 2016 Apr 4. PubMed 27056738 ↗
  • Siegbahn A, Oldgren J, Andersson U, Ezekowitz MD, Reilly PA, Connolly SJ, Yusuf S, Wallentin L, Eikelboom JW. D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy. Thromb Haemost. 2016 May 2;115(5):921-30. doi: 10.1160/TH15-07-0529. Epub 2016 Jan 28. PubMed 26818781 ↗
  • Aulin J, Siegbahn A, Hijazi Z, Ezekowitz MD, Andersson U, Connolly SJ, Huber K, Reilly PA, Wallentin L, Oldgren J. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J. 2015 Dec;170(6):1151-60. doi: 10.1016/j.ahj.2015.09.018. Epub 2015 Oct 3. PubMed 26678637 ↗
  • Brambatti M, Darius H, Oldgren J, Clemens A, Noack HH, Brueckmann M, Yusuf S, Wallentin L, Ezekowitz MD, Connolly SJ, Healey JS. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol. 2015 Oct 1;196:127-31. doi: 10.1016/j.ijcard.2015.05.141. Epub 2015 May 28. PubMed 26093161 ↗
  • Bohm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol. 2015 Jun 16;65(23):2481-93. doi: 10.1016/j.jacc.2015.03.577. PubMed 26065986 ↗
  • Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart. 2014 Aug;100(15):1193-200. doi: 10.1136/heartjnl-2013-304872. Epub 2014 May 2. PubMed 24794140 ↗
  • Verdecchia P, Reboldi G, Di Pasquale G, Mazzotta G, Ambrosio G, Yang S, Pogue J, Wallentin L, Ezekowitz MD, Connolly SJ, Yusuf S; RE-LY Study Investigators. Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). Am J Cardiol. 2014 Feb 15;113(4):669-75. doi: 10.1016/j.amjcard.2013.10.045. Epub 2013 Nov 23. PubMed 24359765 ↗
  • Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014 Mar 4;129(9):961-70. doi: 10.1161/CIRCULATIONAHA.113.003628. Epub 2013 Dec 9. PubMed 24323795 ↗
  • Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013 Nov 19;128(21):2325-32. doi: 10.1161/CIRCULATIONAHA.113.002332. Epub 2013 Sep 30. PubMed 24081972 ↗
  • Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014 Feb 4;63(4):321-8. doi: 10.1016/j.jacc.2013.07.104. Epub 2013 Sep 27. PubMed 24076487 ↗
  • Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom J, Themeles E, Ezekowitz M, Wallentin L, Yusuf S; RE-LY Investigators. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation. 2013 Nov 12;128(20):2192-201. doi: 10.1161/CIRCULATIONAHA.112.000491. Epub 2013 Sep 9. PubMed 24016454 ↗
  • Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, Yang S, Yusuf S. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol. 2013 Sep 3;62(10):900-8. doi: 10.1016/j.jacc.2013.05.042. Epub 2013 Jun 13. PubMed 23770182 ↗
  • Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin L, Yusuf S; RE-LY Investigators. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013 Jul;44(7):1891-6. doi: 10.1161/STROKEAHA.113.000990. Epub 2013 Jun 6. PubMed 23743976 ↗
  • Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013 Apr 2;127(13):1404-12. doi: 10.1161/CIRCULATIONAHA.112.001233. Epub 2013 Mar 6. PubMed 23467860 ↗
  • Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013 Feb 5;127(5):634-40. doi: 10.1161/CIRCULATIONAHA.112.115386. Epub 2012 Dec 27. PubMed 23271794 ↗
  • Bytzer P, Connolly SJ, Yang S, Ezekowitz M, Formella S, Reilly PA, Aisenberg J. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. 2013 Mar;11(3):246-52.e1-5. doi: 10.1016/j.cgh.2012.10.021. Epub 2012 Oct 24. PubMed 23103906 ↗
  • Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S, Kabali C, Reilly PA, Ezekowitz MD, Connolly SJ. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2012 Nov 6;126(19):2309-16. doi: 10.1161/CIRCULATIONAHA.112.101808. Epub 2012 Oct 1. PubMed 23027801 ↗
  • Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M; RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012 Jul 17;126(3):343-8. doi: 10.1161/CIRCULATIONAHA.111.090464. Epub 2012 Jun 14. Erratum In: Circulation. 2012 Sep 4;126(10):e160. Heidbuchle, Hein [corrected to Heidbuchel, Hein]. PubMed 22700854 ↗
  • Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Vinereanu D, Siegbahn A, Yusuf S, Wallentin L. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012 Apr 3;125(13):1605-16. doi: 10.1161/CIRCULATIONAHA.111.038729. Epub 2012 Feb 28. PubMed 22374183 ↗
  • Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012 Feb 7;125(5):669-76. doi: 10.1161/CIRCULATIONAHA.111.055970. Epub 2012 Jan 3. PubMed 22215856 ↗
  • Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011 Nov 15;155(10):660-7, W204. doi: 10.7326/0003-4819-155-10-201111150-00004. PubMed 22084332 ↗
  • Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011 May 31;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747. Epub 2011 May 16. PubMed 21576658 ↗
  • Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011 Jan 18;123(2):131-6. doi: 10.1161/CIRCULATIONAHA.110.977546. Epub 2011 Jan 3. PubMed 21200007 ↗
  • Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, Aikens TH, Yang S, Reilly PA, Lip GY, Yusuf S; RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010 Nov 30;122(22):2246-53. doi: 10.1161/CIRCULATIONAHA.110.973735. PubMed 21147728 ↗
  • Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S; RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010 Dec;9(12):1157-1163. doi: 10.1016/S1474-4422(10)70274-X. Epub 2010 Nov 6. Erratum In: Lancet Neurol. 2011 Jan;10(1):27. PubMed 21059484 ↗
  • Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010 Sep 18;376(9745):975-83. doi: 10.1016/S0140-6736(10)61194-4. PubMed 20801496 ↗
  • Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum In: N Engl J Med. 2010 Nov 4;363(19):1877. PubMed 19717844 ↗
  • Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009 May;157(5):805-10, 810.e1-2. doi: 10.1016/j.ahj.2009.02.005. PubMed 19376304 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2005 to primary completion in Apr 2009, 40 months.

Results were first posted in Feb 2011, 1 year 10 months after primary completion.

Of 83 phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's 40 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2005
First posted
Dec 7, 2005
StartActual
Dec 2005
Primary completionActual
Apr 2009
Results first posted
Feb 10, 2011
Last update
Apr 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00262600
First posted
Dec 7, 2005
Start date
Dec 2005
Primary completion
Apr 2009
Results posted
Feb 10, 2011
Last update
Apr 17, 2019

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Warfarin

Start the discussion